Furthering its commitment to deliver the benefits of simple, high viability cell sorting solutions globally, NanoCellect Biomedical announced it has completed agreements with several key partners to distribute its WOLF® Cell Sorter throughout East Asia and Western Europe. These agreements are a key step in NanoCellect’s strategy to expand the availability of its cell sorting system to academic and biopharma organizations worldwide. This global expansion broadens NanoCellect’s reach to life scientists throughout the world, especially important for those frontline researchers working on COVID-19, who require flow sorting.
In early 2020, NanoCellect announced a partnership with Novogene (Northern China). Later that year, Biostar (Southern China), Genmall Biotechnology (Taiwan), and Filgen (Japan) joined NanoCellect’s global distribution network. In October 2019, the company announced an agreement with Singapore-based Research Instruments to distribute its cell sorter, single-cell dispenser, consumables, and software throughout Singapore, Thailand, Malaysia, and Vietnam. DAON BioSciences was selected as the exclusive distributor for the Korean market. Also in 2019, NanoCellect partnered with Millennium Science to support its sales network in New Zealand and Australia.
In April of 2019, NanoCellect announced a formalized partnership with Bucher Biotec. Bucher is responsible for distributing the WOLF Cell Sorter in Switzerland. Also in late 2019, they expanded distribution in Europe specifically in Denmark, Sweden, Finland, Iceland, and Norway when they signed RAMCON as part of their distribution partnership network. In early 2020, I&L Biosystems was added to provide sales and support in Germany, Austria, Belgium, Netherlands, Luxembourg, France, UK, Ireland, Spain, Portugal, and Italy.
Dr. Will Alaynick, Co-founder and VP International at NanoCellect commented, “NanoCellect is eagerly supporting COVID-19 research efforts by providing a benchtop cell sorter that uses sterile, aerosol-free, disposable cartridges with no cross-contamination between samples. While many core facilities continue to have limited service availability due to the pandemic, researchers who are performing single-cell and 10x Genomics assays, immune profiling, antibody discovery, or functional assays are using the WOLF for optimal sample preparation in their lab, especially in BSL2 and BSL3 settings. These distribution partnerships allow our easy-to-use sorter to reach essential researchers’ laboratories.”
NanoCellect’s microfluidic flow cytometry platform is used by scientists to analyze and sort cells for stem cell cloning and cell line development, single-cell genomics and sample preparation, among other life science research applications. The company was founded in late 2009 as a spinout from the University of California, San Diego. Six years were dedicated to perfecting WOLF’s technology platform before introducing the product to early adopters in 2016. Initial funding of the company was provided by 19 NIH SBIR grants and contracts. Today, Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures (Highlander Fund and Triton Fund), and other private investors continue to support NanoCellect’s growth and success.